In conclusion, with the limitations of a retrospective study, FLAI-5 seems to be an effective therapy for NPM1 mut AML patients, regardless of FLT3-ITD status and may not require the application of HSCT in first CR, especially in patients achieving a rapid MRD clearance [22,29]. The gene discussed is NPM1; the disease is acute myeloid leukemia.